Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | HTR2B | P41595 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.54 |
| ▸ | BID | P55957 | 3/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.50 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.50 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28193718 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL31079007 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1003626 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1002751 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1004554 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL421013 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1004461 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL5566506 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1003944 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 | |
| SCHEMBL1003237 | 1.00 | LMNA (0.58) | LMNAMEN1NR1I2CHRM2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108289886-B | Ion channel inhibiting compounds, pharmaceutical formulations and uses | 安华赛公司 | 2022-01-28 | — | — | CN | disclosed |
| US-8778219-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130338389-A1 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | UT-BATTELLE, LLC (US) | 2013-12-19 | — | — | US | disclosed |
| US-8535560-B2 | Ionic liquids for separation of olefin-paraffin mixtures | UT-BATTELLE, LLC (US) | 2013-09-17 | — | — | US | disclosed |
| US-8034740-B2 | Adsorptivity imparting agent containing porous silica | TAIYO KAGAKU CO., LTD. (JP) | 2011-10-11 | — | — | US | disclosed |
| US-7927634-B2 | Compositions and methods for treating angiogenesis-related diseases, wounds and cosmetic use of components of Angelica sinensis, and methods of preparation thereof | SUNNY BIODISCOVERY, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2011008664-A2 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | UT-BATTELLE, LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015461-A1 | Ionic Liquids for Separation of Olefin-Paraffin Mixtures | UT-BATTELLE, LLC (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100255069-A1 | COMPOSITIONS AND METHODS FOR TREATING ANGIOGENESIS-RELATED DISEASES, WOUNDS AND COSMETIC USE OF COMPONENTS OF ANGELICA SINENSIS, AND METHODS OF PREPARATION THEREOF | SUNNY BIODISCOVERY, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20070166438-A1 | Adsorptivity imparting agent containing porous silica | KABUSHIKI KAISHA TOYOTA CHUO KENKYUSHO (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1721662-A1 | ADSORPTIVITY IMPARTING AGENT CONTAINING POROUS SILICA | TAIYO KAGAKU Co., LTD. (JP) | 2006-11-15 | — | — | EP | disclosed |
| CN-1849320-A | Process for the preparation of renzapride and intermediates thereof | ALIZYME THERAPEUTICS LTD (GB) | 2006-10-18 | — | — | CN | disclosed |
| US-20060068032-A1 | Compositions and methods for treating angiogenesis-related diseases, wounds and cosmetic use of components of Angelica sinensis, and methods of preparation thereof | SUNNY BIODISCOVERY, INC. (US) | 2006-03-30 | — | — | US | disclosed |
| EP-0688559-B1 | Skin anti-ageing composition | SHISEIDO CO LTD (JP) | 2001-06-20 | — | — | EP | disclosed |
| US-6077520-A | ANTI-AGING TOPICAL COMPOSITION INCLUDING AT LEAST ONE OF SULFONYLETHYLENEAMINE OR MERCAPTOSULFONYLETHYLENEAMINE COMPOUNDS OF GIVEN FORMULA AND SPECIFIED ULTRAVIOLET LIGHT PROTECTIVE AGENTS | SHISEIDO COMPANY, LTD. (JP) | 2000-06-20 | — | — | US | disclosed |
| US-5747049-A | AMINOETHYLSULFINIC ACID OR AMINOETHYLTHIOSULFONIC ACID, SUNSCREEN | SHISEIDO COMPANY, LTD. (JP) | 1998-05-05 | — | — | US | disclosed |
| EP-0688559-A1 | Skin anti-ageing composition | SHISEIDO COMPANY LIMITED (JP) | 1995-12-27 | — | — | EP | disclosed |
| US-4472413-A | PSYCHOLOGICAL DISORDERS | BEECHAM GROUP P.L.C. (GB) | 1984-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338389-A1 | IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES | POU2F1, POU2F2, POF1B | LMNA 4185/4885MEN1 1717/4885NR1I2 1669/4885 |
| US-20110015461-A1 | Ionic Liquids for Separation of Olefin-Paraffin Mixtures | POU2F1, POU2F2, POF1B | LMNA 4185/4885MEN1 1717/4885NR1I2 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.